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Biography
Dr. Neil Schechter is the Director of the Chronic Pain Program at Boston Children’s
Hospital, an Associate Professor of Anesthesiology at Harvard Medical School, and the
founder, President, and CEO of ChildKind, a nonprofit advocating the prevention of all
bio-psycho-social pain in children.
Dr. Schechter graduated from Michigan State University, College of Human Medicine
Medical School in 1973 and has been active for nearly 50 years in the field of pediatric
pain. Dr. Schechter has authored over 120 articles, completed several multimedia
appearances, developed several textbooks and book chapters on pediatric pain, and serves
as an editor on international and domestic committees such as the World Health
Organization Expert Committee on Pediatric Pain and Palliative Care and the Task Force
on Chronic Pain in Children of the American Pain Society.
Dr. Schechter’s research focus is now pain of children during common medial practice
such as injection pain and functional pain.
Interview Abstract
Dr. Neil Schechter begins this interview by describing the state of the pediatric pain field
during the late 1970s. As he was training, he “felt it was a bit wrong” to have the
disciplines dealing with physical and emotional/mental well-being so divorced from one
another, especially with unaddressed psychosocial care for pediatric patients and families
during complex chronic conditions such as cancer and sickle cell. Dr. Schechter also
recalls a prevalent fear in the medical community of addicting children to pain
medication, which kept clinicians from treating children’s pain at all.
Dr. Schechter questioned why pain was so chronically undertreated in pediatric patients
and participated in numerous academic research inquiries into how to safely prevent pain.
With a small community of like minds that he fostered, Dr. Schechter ventured forth into
broadly exploring and reframing the way pain was thought of by clinicians.
After Dr. Schechter began to develop a pediatric pain program at the University of
Connecticut, he found that pain was often thought of as a psychological construct that
was divorced from any biological implications. He worried that this commonly held
theory was prolonging harm and suffering experienced by pediatric patients, while also
weighing heavily on the clinicians that were referred to work with the suffering children.
In several of his works, Dr. Schechter investigated common medical practices and
concluded that many of them were causing unnecessary biological and psychosocial harm
to children. He also challenged his clinician peers to think about why they would do
something to children that they would not do to adults getting the same treatments.
Dr. Schechter discuss how his work built on the foundational work of his colleagues and
peers. He recalls several instances he was able to rally similar minds to collectively
publish research texts informing and advocating for medical practices to change.
In his local institutions, Dr. Schechter was successful in advocating for institutional
reform to improve care that was committed to causing no further biological or

Interviewer: Bryan Sisk
Interviewee: Neil Schechter

June 28, 2019
Page 2 of 34

psychosocial harm to kids. This also spurred him to found the nonprofit ChildKind that is
committed to aiding institutions in preventing pain for pediatric patients.
Dr. Schechter then goes on to describe the various challenges he faced in his career
including peer clinician resistance, divisive national sensationalism of his work, and
medical models that were incomplete or lacking in understanding of holistic human wellbeing. He also explains that some of the bad habits of the past are continuing into the
present day practice.
He concludes the interview by describing practices that could be altered to achieve a
better understanding of patient health, such as reexamining why hospitals don’t prevent
needlestick pain when it is within their ability to do so. Dr. Schechter also celebrates the
positive advances that have been made for pediatric pain.
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Abbreviation
AIR
BMJ
CBT
CEO
COG
ED
DPT
GI
HCAHPS
IM
IBD
IOM
ISPP
IV
JCAHO
JIA
MRI
PCA
PDA
PMR
UN
WHO

Glossary of Acronyms
Definition
Assessment, intervention, reassessment
British Medical Journal
Cognitive behavioral therapy
Chief Executive Officer
Children’s Oncology Group
Emergency Department
Demerol, Phenergan, Thorazine
Gastroenterology
Hospital Consumer Assessment of
Healthcare Providers and Systems
Intermuscular
Inflammatory bowel disease
Institute of Medicine
International Symposium of Pediatric
Pain
Intravenous
Joint Commission on Accreditation of
Healthcare Organizations
Juvenile idiopathic arthritis
Magnetic resonance imaging
Patient controlled analgesia
Patent Ductus Arteriosus ligation
Physical Medicine and Rehabilitation
medicine
United Nations
World Health Organization
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Okay. Today is June 28th, 2019. I am Bryan Sisk and I am in St.
Louis, Missouri interviewing Dr. Neil Schechter over the telephone
for the Pediatric Palliative Care Oral History Project. Dr. Schechter
is in Salisbury, Connecticut. Thank you, Dr. Schechter, for joining
me today. To get it started, could you tell me when your mind
turned to a pediatric pain as a career focus?
Yeah so, I was always interested in the interface of the
psychological and physical in pediatrics. Of course it has
developmental piece as well; so it was sort of an interesting
interface and that was always my interest. At one time I actually
considered being a psychologist. And when I went to medical
school I considered the possibility of psychiatry, but that just didn't
resonant with me because it didn't emphasize, when I went at least,
the biological side as much. It was much more strictly mind
separated from body in a way that was, I think, unreasonable at
that particular time, we now know to be felicitous.
Anyway, so I did pediatrics and after I finished pediatrics I was
still a bit unsure of what I wanted to do. I spent sort of a gap year
at the Indian Health Service out in the Dakotas and returned as a
chief resident at the University of Connecticut. The chief there was
a lovely man who took a real interest in my career and really was
fundamental and helping me shape my thinking about things. He
suggested a fellowship that had crossed his desk that might suit my
particular interest and desires. That was in what was then called
psychosomatic pediatrics.
It was at Boston Children's Hospital at that time. It had only been
going a short period of time and it was basically focused on
individuals—children who had psychological problems that
amplified their physical problems or vice versa. So, in other words
somebody with—excuse me just one second, I have my alarm set
here. Somebody for example with diabetes who, for a variety of
psychological reasons, would be unable to care for themselves or
those sorts of issues and we run this unit.
I was a pediatric fellow, there was a psychiatric fellow, and then
there was a head nurse. We had a number of interesting attendings
who attended on this unit. Some of the kids, who just stumbled
through at that time through this unit, where they would stay for
prolonged periods of time, were kids with pain problems that were
ascribed to psychological origins. Even though the psychological
origins at that particular time were really not necessarily evident,
they were assumed because the hardware that was examined in that
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era didn't reveal any underlying disease process, yet they were
suffering and incapacitated.
So they were put in this unit in and spoke to psychologists for long
periods of time. The medical piece was really de-emphasized.
Simultaneously with that I was offered a fellow—and that sort of
whet my appetite because something felt a bit wrong to me with
that. This was like in the late '70s, maybe '77, '78. Around that
time, I was offered another fellowship there in developmental
pediatrics which really was a fusion of the biopsychosocial model
in a way that almost nothing else in pediatrics was true
legitimate—looking at temperament individual differences, the
biology of differences, biological vulnerabilities of adverse events.
A couple with sort of psychological.
It fused a lot of the things that I was interested in at that particular
time. Part of that program focused on learning problems and other
things, but there was an interesting abdominal discomfort,
abdominal pain, with a specific sort of model at that time. And that
model was a fair amount more biologically based. But anyway, I
had some interest in that and the clinic I participated in as a fellow
didn't think much of it.
I was then hired to begin the development of pediatrics program at
the University of Connecticut and a couple of things happened.
Number one, there was—because the academic psychiatrists were
not particularly helpful with a lot of the conditions that they were
facing, especially around kids with medical problems, a lot of them
ended up on my doorstep. I wasn't particularly prepared to deal
with them either, but the psychiatric piece, the simplistic unidimensional piece really wasn't helping a lot of kids with cancer,
kids with sickle cell in particular, and a number of other problems.
About that time, I had to cover the wards as well, and there were a
number of kids we had with sickle cell disease. That became a real
interest of mine because I wasn't sure what to do with these kids.
They were really complaining continuously of discomfort. The
specter of addiction hung over them continuously. It was
introduced by everyone from the nurses, and anytime they would
ask for more medication there was an eye roll.
Anyway, just about that time, I started to review the literature on
sickle cell pain and there was an article and I remember it very
clear to this day because it was seminal for me by people called
Marx and Sacker. I think they were at Einstein or something at that
time. And the article took 38 consecutive sickle cell patients who
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were complaining of pain and thought to be addicted and suggested
that they were grossly undertreated. And this is in adult literature
this was not pediatric literature. And when they were treated more
and claimed they had what they would call in this article, or at least
came to be known as pseudo addiction, maybe given 5 mg of
Oxycodone and or whatever. And then in four hours, undertreated,
would wait for that four-hour interval to be up, buzz in
immediately in that period, which was immediately assumed to be,
of course by the medical staff, indicative of addiction or it's an
obsession with the medication.
Anyway, Marx and Sacker said something quite the opposite. So
that really intrigued me and I started to look at that time—my eyes
were opened with that little, it's almost like a can opener. I don't
know the metaphor you would use to explain it, but suddenly I
started to look at almost everything that we were doing at that
particular time and recognized how little attention we were paying
to the comfort aspects of things, to the symptoms that people had.
We were just working with the basic assumption that once we cure
the disease, if we can cure the pain, the symptom would go away.
And that obviously was not the case with sickle cell disease and it
certainly wasn't the case with a lot of the other conditions that we
were grappling with.
So anyway that was one stream and from that stream we got
interested in a number of different things. Just trying to figure out
ways that we could ameliorate that. For example, we were first
little group, and this was just in a little small university hospital—it
was a community hospital part of it—we tried PCA [Patient
controlled analgesia] which just emerged for the sickle cell
population. But the interesting thing was, there was a revolt by the
medical staff there at this particular hospital saying, "You're
allowing free access to their veins with an addictive agent to inner
city kids who are going to abuse this." There was a very strong—
we only wrote a small pilot study about that and I think in the pilot
study if you want to look it up, I even mentioned how emotionally
tinged this whole thing was and the problems that we had with
using PCA for this population given all of the strength of emotion
around them. But simultaneously with that, I started to recognize
the real limitations of this literature and that same of the pediatric
literature on pain just in general.
And so, the first thing I did was, it turned out that my chief of
pediatrics was the guy who did the, I don't even know if it still
exists but Current Problems in Pediatrics. I don't even know
whether that still exists anymore, but it was sort of a monograph
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that came out monthly on a particular problem, maybe 80 pages or
something like that typically. And he said, "You know what? Why
don't you write one on pain." And I think that was like in 1984, or
'85. And as I started to write this and collect information, it was
stunning how little we knew. Stunning. And when I wrote it and it
was published, suddenly there was a small community of people
who contacted me, who felt similarly. There were people from all
over. There was a Canadian contingent, mostly psychologists.
There was a nurse whose information I came to value very highly
and enjoyed. Even did she come up in your—
[00:10:35]
Bryan Sisk:
Neil Schechter:

Yes, her initial paper that was in that book.
She wrote that book exactly. I actually wrote an obituary on her
when she died a little while ago. But so she wrote—you're exactly
right Bryan. She wrote this really not very—did this not very
sophisticated study, but taking 25 kids on the wards at the
University of Iowa hospitals who were all post-op and looked at
the type of post-operative care that they received in terms of pain
management in particular and it was shocking; 25 kids something
like 24 doses of anesthetics through their hospital stay, half of
which were opioid. So 25 kids, 12 doses of opioids in total.
Kids who had 20% body burns, fractured femurs, palate repair, a
whole host of conditions that one would have thought nowadays
would receive a lot more attention. Anyway it was a pretty
unsophisticated study and so with the combination this increasing
interest that I had looking at that literature, we decided to start to
look at this in a more scientific way. So in the mid-80s we
published this paper on the status of pediatric pain control of
analgesia usage. We took four hospitals in Connecticut. Some
were—I had a medical student or research assistant, and we called
the charts and looked at four identical problems; 20% body burns,
fractured femurs, there were four conditions.
Some in the hospital for more, some from less time. And what was
shocking was that no matter what hospital setting, one rural, one
academic, the adults received four times the amount—we
compared with adults for similar problems—four times the
amounts of doses per day that kids got for the same exact
problems. And when the kids did get anything, it was IM
[intermuscular] and was all predominantly Demerol. That was sort
of way of thinking in that period. So, then we decided to
investigate why that was so. So we published a paper a few years
after that where we surveyed family practitioners, pediatricians,
surgeons, I think those were the groups. I think.
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And I might be off the track I can't exactly remember. But anyway,
what came out of that paper was really intriguing to me, which was
the fact—we asked people, "When do you think kids feel pain?
What do you think about this procedure, that procedure, how
painful it is?" And what striking was that everybody thought that
what other people did caused pain and when they thought didn't
cause pain. For example, the surgeons were concerned about the
bone marrows that we were doing at that time or the lumbar
punctures or other kinds of procedures—rating that as higher pain
than some of the surgical post-operative surgical pain. The
pediatricians obviously thought the opposite. They felt what the
surgeons did, and everybody thought circumcisions were
uncomfortable because they were at that period done primarily by
obstetricians.
So everybody was blaming everybody else but that was in the back
of their minds the recognition that clearly there was some
discomfort. Although almost 25% of the samples didn't feel the
kids under the age of two felt much pain. So anyway, all of these
things then led to sort of a low hanging fruit that was out there
about ways to start to think about this in a more critical way. So
that was some of the PCA work we did.
I think that was very interesting because I was working with at that
time a pediatric oncologist named Steve Weisman who got so
interested in pain after we started working together that he went
back and started doing anesthesia. But we together did a couple of
papers looking at a cancer pain in particular.
One of the things we started to do initially was just to survey
cancer centers around United States to find out what they were
doing for sedation, just in general. And there were 33 different
regimens largely chloral hydrate, which is you know is not
analgesic. And this has been in this era. This is for bone marrows.
The primary one, I don't know if you've even heard this, this is all
going to be so archaic, but was something called DPT [Demerol,
Phenergan, Thorazine], did you ever even hear that?
[00:15:26]
Bryan Sisk:
Neil Schechter:

No.
That was something developed in the '50s by the French to induce
what they call "suspended animation." It was a combination of two
phenothiazines. Let's see, what was it? I can't even remember what
was in it anymore—Demerol and Morphine, something like that. I
can't remember even what the combination was that they
developed. But anyway that is what was used typically when
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anything was used. It’s about 12% incidence of significant side
effects with it. It's terrible, but when people were doing anything
other than chloral hydrate, that's what they were doing. So, then we
said about one of things—the direction we went in was—I'm
talking more than perhaps I should. Maybe I should let you.
[00:16:09]
Bryan Sisk:
Neil Schechter:

No, please go on. This is wonderful.
Okay great. So anyway, we then decided to take it in different sorts
of directions because there was just such low hanging fruit there,
almost everything—no one was thinking about any of these sorts
of issues. So from the research side we started to investigate
looking for different types of clamps for circumcisions. We looked
at different types of approaches for injection pain. And in
particular I read this little blip like USA Today or something on a
plane about Fentanyl lollipops that were being developed by this
guy Ted Stanley and they were developed for preoperative
sedation, is what they were developed for, but in my mind, I
thought, "God, those would be great for kids for sedation like in
the ED [Emergency Department] where we would not have to start
a line, or we could sedate the kids." And so we convinced them to
develop a version of this for kids and we studied it prior to bone
marrow aspirations and bone marrow biopsies. The problem with
this a lot of vomiting associated with it downstream, but when we
did, we thought it was a great idea and it was helpful.
One of the studies that we did that came out of that, which sort of
was one of the more interesting things that we did I think and is
still quoted pretty frequently, was a study were we got each kid
who was enrolled on the study—at that time we were doing
nothing but localized anesthetics for the most part 1. And so, this
kid who's enrolled into this study was given either a Fentanyl
lollipop or a placebo lollipop. And obviously the placebo lollipop
kids have more pain than a Fentanyl lollipop. All the kids these
kids had leukemia and they all required multiple bone marrows
downstream. So for all subsequent bone marrows we gave them
active drug whether they were in the placebo group or the control
group. Yet the group that had initially negative experience, the
placebo group, graded their pain as higher even though they had
active drug after four bone marrows downstream, which told us
obviously the critical importance of aggressive sedation earlier on
in this process and the importance of expectation and doing
adequate job in the beginning, so that we don't develop this failure

1

Weisman, S., Bernstein, B., Schechter, N. (1998). Consequences of Inadequate Analgesia During Painful
Procedures in Children. Arch Pediatr Adolesc Med,152(2):147-149.
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of sedation so the kids don't develop sort of ongoing anxiety
around this.
Anyway, those are some of the papers that emerged during that
period. It was at that period as well that we first International
Pediatric Symposium. It is called International Symposium
Pediatrics—let's see International, I-S-P-P—International
Symposium on Pediatric Pain. The first one was held in 1988 and
there were about 60 of us there and from around the world really. It
was in Seattle. That was a gathering—I met a couple of other folks
there and we decided to write the first textbook in this field. So we
wrote the Pain in Infant Children and Adolescents 2. We decided to
do it on a boat in Seattle Harbor and five years later we had the
first edition out in '93 and we had a second edition later. And that's
where a cluster of—some of the people who are still active in the
field now, Chuck Berde, a number of us we're still together, Elliot
Krane out in Stanford—a number of other folks were there at that
sort of first.
That also put in my mind increasingly we were working with
Steven Weisman and the head of the oncology at our program who
was interested—he was a lovely man and he was interested in
doing something more for pain for kids with cancer and listened to
our lollipop work or this was actually prior to it. So a family who
lost a child to leukemia I think it was, gave him a little bit of
money and so we organized sort of this conference consensus
meeting on cancer pain that we held in Chester, Connecticut. And I
think we published a supplement to pediatrics on that, five
different aspects of it; Sedation or procedure related pain, disease
related pain, and a number of other aspects of that. Steve and I
were editors of that, and then there were five sections on that. But
again we started to set the mark for that. Around simultaneously
with all that a couple of years later, staying in your arena or the
one that you’re interested in, Kathy Foley—and I'm not sure if you
know who that is. Do you know who that is?
[00:21:09]
Bryan Sisk:
Neil Schechter:

2

Mm hm.
Yeah so Kathy Foley, who was an incredible person at Memorial
Sloan Kettering, and actually she was one of the people who added
to my interest in cancer pain because they had what was called an
observership at Memorial and you could spend a couple of weeks
there just looking at what they were doing. They didn't have any
pediatric work there but it gave me the mindset to go back and do

Schechter, N. et al. (1993). Pain in Infants, Children, and Adolescents. LWW
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what they were doing for adults, for kids at our little hospital. But
anyway Kathy Foley was contacted, I think with the WHO [World
Health Organization] liaison a woman named Lucia Benini who
was an amazing person, is an amazing person still; lost a daughter
to cancer at the age of 13 and decided to devote her life to
symptom relief.
And so, she funded the first major WHO pediatric cancer pain
meeting that was in Gargonza, which is a little walled Italian
village where her daughter used to spend summers. And so she
brought 20 of us there. And we divided up into groups and came
up with some guidelines based on very little information available
to us but based on best practices, because by that time there was a
fair amount of more sophisticated practice. Anyway that emerged
from there. There was quite controversy with that particular time,
but anyway that happened as well.
But that could happen and a lot of this could happen because of the
development of some assessment techniques to gauge pain in kids,
because obviously older kids could tell you something about their
discomfort, but kids three to eight had the ability to sequence
things, to seriate things, put them in an order, but really didn't have
the—they were more concrete and couldn't sometimes give
numbers. So there was a whole development that we still use,
cartoon versions of that, color versions of that, facial expression. A
whole host of other things that we use for that group.
And then there was a development for instance of all these
behavioral measures that emerged; a lot of them develop by nurses.
A lot of them Canadian nurses who did a lot of this work.
Anyway, so we had some more techniques to start to measure
some of those stuff so we could do some this research and look at
what made a difference. Gradually they got to be a larger and
larger group. By '94 this small little group that was 60 people or
something, in 1988 was about 300 or 400 in Philadelphia and then
it grew and grew and grew. In the last meeting actually, I just got
back from which was in Switzerland, and I was there when you
contacted me and it's the 12th annual and there were 800 people
there. So the field has really expanded very significantly over time.
The only other thing I will just mention around these lines again to
stay with palliative care mode was that, maybe it was—I know
exactly when it was, it was 2001 because we were in Washington
D. C. when the planes hit at this Institute of Medicine committee
called "When Children Die." And that was sort of a developing an
IOM [Institute of Medicine] consensus meeting basically and we
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published a book on palliative care for kids. Marcia Levetown was
on that group and that's where I got to meet her. Again, I was the
pain person and not the palliative care person, but I was able to
contribute to that.
And just to continue with my own career arc a little bit more and
then we can start to get into whatever else you want to get into. So,
as we started, as more and more anesthesia people and as we
developed more assessment techniques and more sophisticated
pharmacodynamics, folks got in there and we started to be able to
know how to use these drugs more effectively and what their
impact was. It felt to me, who was not a scientist in that sort of
way, that I could move on to other kinds of things so that's where I
got more interested in primary care related pain problems, injection
pain, and a number of other kinds of pain problems; in particular
chronic pain. And that's where I spent the last 10 or 15 years really
as focusing in chronic pain in particular, those sort of pain
problems which are very incapacitating.
There's no obvious hardware, let's continue with that metaphor,
hardware anomaly, yet the suffering was just as real. They're often
disbelieved as not, it requires a trusting relationship. Many of the
kids we've seen have been seen by many, many people already
who'd been either over investigated and sent off to a psychologist
or sent to a psychologist more immediately or more recently—we
wrote an article coming out of Pediatrics—more recently then
given diagnosis that are expansion of traditional diagnosis that
used to be quite rare. In particular I'm talking about—I don't know
whether you encountered this, but it was Danlos syndrome, mast
cell activation disorder, mitochondrial disorder, a bunch of things
that have specific definitions. Lyme disease—people have
expanded dramatically those definitions because they're a part of
their symptom profile; vague sort of symptoms that are similar to
some of the problem set that we're dealing with this population. So
anyway, so one line of investigation, and I've been interested in
that. We're looking at quantitative sensory testing to see whether
the nociception is different in that population.
But the other whole arc of my career has been taking what we
know and figuring out how to apply it more directly because we
know a lot. We didn’t in the 80s and early-90s and mid-90s, but by
the late-90s we knew a fair amount and we knew enough so that
most of it, I mean with rare exception obviously there are some
kids with cancer or some problems that we really struggle with, but
for the most part if we would apply what we know in a uniform
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manner, we can assess and treat the majority of pain problems that
we encounter. But we don't for a bunch of reasons.
I became interested in that knowledge translation piece and in
particular focused in on institutional commitment to pain
management. Not at a pain service level but throughout the entire
institution so that everybody is aware the pain is an institutional
priority, through signage, through a whole host of other ways
through CEO [Chief Executive Officer] support, through mission
statements, things like that.
And so we started something like that at one of the academic
hospitals I worked at called St. Francis, where we developed
something we called "The Ouchless Place," which was a pledge to
families that we would pay attention to pain as a part of the child's
admission. And when I moved from there to Connecticut
Children's and brought that same concept, they made the same
level of commitment. There we called it "The Comfort Central,"
and there were signs in elevator, new hires were told this, there
was education, it was ongoing. A whole host of things that we felt
were critical and again I published two papers on this if you're
interested.
And then we took it to the next level. In about 2006 or '08, we
talked to the special interest group on pediatric pain, which you
know is basically that ISPP group that I told you about, and got
their permission to develop a non-profit which would recognize
institutions that did a particularly good job in this arena and give
them a sort of a logo and a seal of approval if they met criteria, and
there were six, five principles that were felt to be critical.
We were fortunate enough to get some Rockefeller Foundation
support and we went to Bellagio, Italy and brought in people from
around the world from 13 different countries—20 of us or so to
develop these criteria. And so over the past ten years we've really
been grappling with this, but we developed something which is
called ChildKind. It's actually ChildKind International and we’re
revamping our website. Now there's about 10 or 12 hospitals that
are ChildKind Hospitals. Around the states there's about 10 or 12
in the pipeline. There's a couple that are pending internationally.
And simultaneously with that, all of the hospitals had to contribute
their protocols and educational initiatives or whatever to a website
that would be available to everybody so that institutions that didn't
have the expertise on board could benefit from the templates that
were created by institutions with more expertise.
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And that's where I spend a chunk of my time these days doing that.
There's a couple of—I just wrote one paper on it in Pediatric Pain
Letter that describes the whole ChildKind thing but there's two
other papers that I wrote about that whole concept of institutional
commitment to pain. So that's a big blather on my part but that
gives you a little bit of the arc. It started out with the recognition
that this was an issue. Then one stream of information, the
gathering of information through the initial monograph. Then I did
pediatric clinics in North America and that led to this textbook. So
that was the one whole piece of information.
Also, I have been on a zillion committees, again, that were
consensus committees consolidating information that we had. The
WHO committee on cancer pain, the American Pain Society
meetings on chronic pain, the Cochrane Group, we have a Lancet
commission on pediatric pain, there's our consensus meeting on
needle pain—so, one thing after another. So that's been that whole
sort of information gathering, consensus building, advocacy piece.
And on the other side there's been the investigation piece which
looked at the initial differences, some of the attitudes that foster
those differences in prescribing. And then little projects here and
there that attempted to at least chip away at issues to make things a
little bit better for kids who are encountering medical care. So
that's kind of the story, I guess.
[00:32:55]
Bryan Sisk:

Neil Schechter:

[00:33:37]
Bryan Sisk:
Neil Schechter:

What a story. Wow. I have a bunch of branch off questions.
Starting it back at the beginning and working our way up. One
thing I've been really wondering is about a lot of this history what
the on-the-ground reality was. And so first I want to think about
that U.N. [United Nations] article that came out. My understanding
was that was a chapter in a fairly obscure nursing textbook.
Yeah, I’m thinking about it. I’m not sure how true it was, but yes
that is what is was, it was a chapter in a nursing textbook quoting
her master's thesis which I got a copy of from the University of
Iowa Library. That's exactly what it was.
So how much of an impact did that have initially?
So that had huge impact. Huge impact. Again, not in the medical
community per se. In the nursing community however, it became
very well-known. And in that particular time there were a number
of nurses, Margo McCaffery was one from the adult side. There
were a number of nurses who were leading the charge. Again,
because when you close the door and the doctor goes off to chart
and whatever else they have to do, the nurse is sitting there.
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So, it turned out to be a lot of the assessment stuff all the pediatric
assessment stuff Judy Beyer was in Colorado. She did the Oucher,
Celeste Johnson and Bonnie Stevenson developed all the preterm
and infant pain stuff, the infant thesis stuff. Donna Wong
developed the sort of Faces scale. All that came out of nursing, so I
think it had a dramatic impact on nurses per se.
I'm not sure honestly, it's too far back for me to remember how I
came up with it but I have a feeling and there wasn't such a thing
probably as PubMed at that time, but somehow I must have seen it
referenced in something that I was looking at and then went back
and looked at it. But then she became famous for the sort of myths
and misconceptions that she felt that promoted that undertreatment.
The main one was that the kids didn't feel pain, that their nervous
systems were underdeveloped and really, they didn't experience
pain. But that was the main one that she implied and obviously
neuroanatomically there are differences in a developing nervous
system but that has nothing to do with it though.
We know that at multiple levels now in a much more sophisticated
ways with fMRIs [Magnetic resonance imaging] and everything
else. But we obviously knew it just sitting in the room; didn't take
a genius to know that somebody was suffering. So that was very
impactful for some of us and those myths are still quoted even to
this day I would say when people do this. But again, how that got
from that, as you mentioned, from that textbook to being the coin
of the realm for those of us who were interested, I don't know.
There was another thing that spread similarly which was
unfortunately problematic. But again, these things, people were
looking for things that would support their observation. So the
other thing which was really important, and that was, what's his
name? Somebody Jick. I forgot the two names. Anyway, it was a
letter to the editor of the New England Journal in the '80s, and it
was from two people who ran what they called the Boston Drug
Surveillance Project. This was a letter to the editor 3. It wasn’t an
article and they reported on 11,000 adults. These were all adults.
This whole literature is adult. Who received Demerol post-op and
four of them became addicts, stating that they didn't think there
was a genuine risk of addiction in people who used these
medications for legitimate purposes. And that became part of our
conventional wisdom I would say; had a life of its own and was
part of the belief system of most of us because we were convinced
that, that was so.
3

Porter, J. & Jick, H. Addiction Rare in Patients Treated with Narcotics. [Letter to the editor]. New
England Journal of Medicine, Vol 302(2), 123.
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But anyway, yeah so that's how the Eland thing got about. The
intriguing thing is that Jo would lecture but she was a nurse. And
when she would do ground rounds, as you could imagine
especially in that era, there was limited respect given for her
opinion. And again, she was talking to groups largely of surgeons
who had a practice pattern that totally denigrated pain. And it was
hard for somebody who's been doing something for 25 years and
causing significant discomfort, but you've had enough cognitive
dissonance to think that, "You're not really doing that. It's not
really causing that much pain. You're doing an adequate job."
For somebody to put that in your face, especially if it’s a nurse,
was really unacceptable. So we on rounds together and literally she
would be attacked by these people and I have to stand up there. At
some of these I remember very specifically at one upstate New
York hospital where there was an angry surgeon responding to
this. And again, because I'm not an acute care person my
credibility wasn't that much better. I would say I was in between a
nurse and a surgeon and but even so I was a lot better than her. But
that is how it was. The field was very non-responsive, especially in
the newborn world. In the newborn world it was bad enough for
post-op, but in newborns, we were obviously doing circumcisions
but above and beyond that, we were putting test tubes in babies
without any sedation. We hardly had any local anesthetics typically
doing LPs [lumbar punctures]. The markers were thought to be
blurred if we put in local—so there were all kinds of things that we
were doing that was real, real cognitive dissonance in that period.
And that probably until Sunny Anand’s work—are you familiar
with that?
[00:39:13]
Bryan Sisk:
Neil Schechter:

Mm-hm.
Okay. Until his word came out and codified the massive
outpouring of toxic hormones if you will, that occurred when
somebody did a PDA [Patent Ductus Arteriosus] ligation with and
without anesthesia. Suddenly as soon as that work came out, seven
journals came out with editorials saying it was barbaric to do it any
other way. So you know little by little that was disruptive
technology or whatever you call that these days. So, that was
Eland’s thing and I don't know how it spread. I got to know her
very, very well. She came to this house out in Berkshires actually.
She was a marvelous person. And then she took it at the next level.
She trained her nurses, she developed work-ships, they went to
Italy, and she developed with Lucia Benini who funded some of
her padres of nurses who trained other nurses there in Italy.
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She then did the same thing in India. So she just spread the word at
the nursing level and a lot of the nurses were taught to demand
accountability for this and that's been one of the issues. Who's
accountable for this pain? And if you can't do it, who's the next
step up in the chain to demand that to make it go through their own
chain of command? And so she emphasized the humiliation of
people who were not doing adequate job with this, "If you don't
know enough to do this, then look at this paper. If you don’t
enough, who's your attending?" Yeah so anyway that's the Eland
story. She became a hero really and developed the American side
of pain management nursing and a bunch of other kinds of things.
[00:41:03]
Bryan Sisk:

Neil Schechter:
[00:41:26]
Bryan Sisk:
Neil Schechter:

[00:43:06]
Bryan Sisk:

4

So, we talked about how some of these cognitive dissonance and
some of these just lack of awareness or appreciation of the pain
that mainly physicians were inflicting was one of the barriers to
effective pain management. Were there any other barriers?
Well, I'll tell you a story. Again, we have time, right?
Yeah, I'm on your time. You're my last one for the day.
Okay great. So, the paper we published in '86 on status
of analgesics usage in children 4, the one that I mentioned initially.
That was my first major paper I published paper in clinical reports
or something like that. I was in an institution at that time. Now I'm
at a fancy place and they have a very strong public relations
department, public information department that would protect me
basically. In other words, they would send people with me so I
wouldn't be misinterpreted, all that kind of stuff. But at that
particular time, I was at the University of Connecticut and there
was no such thing really. And so, I published this paper and the
way it was interpreted, even though if you re-read it sometime in
your leisure if you choose to, I was very conscious and not trying
not to be a self-righteous prick and the accuse everybody of doing
a bad job and saying "you're doing a terrible job." I was merely
pointing out, there were differences between adults and kids, and
we can do a better job. But the media loved it. They loved it and
they thought that I was the canary in the coal mine calling out
something, that's probably not the right metaphor because we were
all not dying, but that a hero was—
The whistle blower almost.

Schechter, N., Allen, D., Hanson, K. (1986). Status of pediatric pain control: a comparison of hospital
analgesic usage in children and adults. Pediatrics, Vol 77(1), 11-15.

Interviewer: Bryan Sisk
Interviewee: Neil Schechter

Neil Schechter:

June 28, 2019
Page 20 of 34

The whistle blower. The Puritan standing with the light and
exposing all these horrible doctors who were doing all these
terrible kinds of stuff. So they loved that. Suddenly I get home
from work that day, and I was exhausted and it had been published
that day, and my wife says, "Where the hell are you? You’ve
gotten 40 phone calls about this." And some guy from the AP
[Associated Press] calls, I call back and he says, "I haven't had the
time to read the 100 word synopsis of this article—can you tell me
it?" And what they're trying to do, it felt to me, was to have me
oversimplify and give non-nuanced sort of statement about what I
was trying to do.
But anyway, regardless of what I tried to do, I felt it was entirely
misinterpreted. I was even on Good Morning America, one of
those shows and in the morning, and the guy was basically—I was
trying very hard not to be in anyway inflammatory to suggest that
this is—because people are bringing their kids to hospitals. And
suddenly they're informed that—you can just imagine if your kid
was scheduled for surgery the next day, that's probably 200,000
kids around the country and somebody is saying "more than likely
your kid will suffer unnecessarily."
So anyway, this spun out of control. I couldn't stop it and I was
scheduled for some other interview and I was constantly trying to,
not undo but nuance this. And the guy said, "I'm sorry, we're
scheduled to have you, but would it be okay if we postponed this?
The challenger missile blew up." I don't know if you remember,
but in '86 I was with a teacher who was on the spacecraft and was
one of the seven astronauts who died. And so I said, "You know,
I'm good with that and I'll flash in the pan. If I flash in the pan
again you can call me, but I'm done with this."
So anyway, that was what we were facing at that particular time.
There was a lot of blow back. There was a lot of misinformation.
There was a lot of resistance. Although surprisingly not as much as
I anticipated especially when the data was out there about how to
do this in a better way. So for the most part, people relatively
quickly latched on to some of these things. There were still subtle
things, Nuss procedures, scoliosis, there are still procedures in
which we didn't have good protocols in place. But for the most part
the typical kind of pain scenario we started doing a better job.

[00:45:56]
Bryan Sisk:

How much did fear of not knowing how to dose this or fear of
harming the children with the medications, how much do you think
that figured into this hesitance.

Interviewer: Bryan Sisk
Interviewee: Neil Schechter

Neil Schechter:

June 28, 2019
Page 21 of 34

I think a fair amount. I think a fair amount in the beginning. We
really didn't know the dosing, so we tended to use what was then
called weak narcotics; codeine in particular was used and you
know the deal on codeine right now—the lack of an enzyme that
10-40% of people have. And so, they were given acetaminophen
with codeine in it and they ended up with basically
just acetaminophen. Or it was rapidly metabolized and they ended
up having side effects in about 10-12% of people. But that is what
we were going to, if you will, because they thought that was safer.
The other thing was IV [intravenous] medications. In the beginning
people were reluctant to use these meds on the full IV so they had
to be used IM or orally because they thought these kids needed to
be monitored before they used any of the IV opioids. Again, it
sounds like an entirely different world as you can imagine. But
there was some genuine reluctance to do that out of fearfulness.
That turned around relatively quickly, especially when there
started to be more consensus statements about it. So, there were
some back up, if you will, against the possibility of litigation or
other kinds of things happening if the professional societies were
endorsing these kinds of things.
But in general, that was the lack of knowing how to do it. But what
we ended up doing was IM Demerol and that was the standard of
care. And just imagine that it was every four hours and just
imagine if you had to call the nurse to say that you were in pain
and you knew she was going to come in with a big needle. You
would not. It would quickly be a disincentive, if you will, to say
you're in discomfort, to say you're in pain.

[00:48:26]
Bryan Sisk:

Neil Schechter:

So you talked early on when you were going through your training
and fellowships how there was kind of this sharp distinction
between psychological issues and pain issues and physical issues.
When did those concepts start to blend into a more holistic view of
pain, in a more holistic view of patient experience?
Well what do you think? What do you see now? I mean I was at a
meeting and I was giving a talk on chronic pain. And actually the
talk I give is on the origins of the nomenclature for these
conditions, functional conditions if you will. I'm not talking about
right now, but you actually can have persistent pain in kids with
cancer who's under control, right? With kids with sickle cells
whose episode is under control. Kids with IBD [Inflammatory
bowel disease] whose inflammatory markers are fine, but you still
have sort of a hyper sensitive nervous system that is overly
responsive. So I would suggest that even to this day, there's still a
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lot of a dichotomy between people who say, "Well he doesn't look
like he's in pain."
Well, a lot of that still exists to this day. From the pain world, I
would say in the past 15 years or so, but the most recent edition of
Stedman’s—which the printed one was in like 2006, that is about
what 10, 12 years ago something like that—it says functional
disorders and it says something where, "the symptoms without an
obvious organic explanation," blah, blah. And then it says,
"See neurosis." So as late as that, they were still making that sort
of distinction, even though we obviously do not think that is the
case at all anymore. That obviously anxiety and depression might
amplify a biological vulnerability, but is not the cause of it
typically. But the field still dichotomizes this a bit I would say.
Sophisticated folks don't—I know in your training where you go—
so sophisticated folks for headaches, for functional abdominal
pain, for fibromyalgia, for IBD, they'll still stick. They will have to
explain it using of metaphors and a whole host of other things—
that your pain, more investigation is not the solution to this but that
does not mean that this is an incapacitating pain and that your
nerves are like sun burned and hypersensitive. So that's actually
some of our recent research in kids. But I would say even to this
day there's still that Descartian sort of dichotomy.
[00:51:13]
Bryan Sisk:

And as your data was coming out, you know the Eland came out,
your data followed it in the mid to late-80s.

Neil Schechter:
[00:51:21]
Bryan Sisk:

Correct.

Neil Schechter:

Yeah I would say stunningly; number one we started to have more
assessment stuff, which was great. But stunningly it was Sunny
Anand's work in 1987 or '88 that really changed everything. As I
mentioned, if you look shortly thereafter there were in the BMJ
[British Medical Journal, in the New England Journal, in
Anesthesia & Analgesia, every major journal started to say it is
barbaric to do what we historically been doing in terms of the lack
of adequate treatment of pain and the lack of adequate anesthesia.
So that sort of did it.

What was the gap between that data coming out and starting to see
major changes in actual practice? When was the data able to crack
through some of the resistance you were getting from the surgeons
and from other physicians?
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There was still resistance. People still didn't know how to do it, but
there was a mindset change especially in the younger physicians.
Now again the younger physicians in their training are very much
influenced by senior physicians and so there were still settings
where that was so. But chief residents, other folks who were at the
top of their heap, if you will, started to incorporate these things and
it really took time. And again, I don't know other settings. I mostly
know my own setting.
But even to this day, if you do a blitz in hospitals, folks at Sick
Kids for example did a blitz a few years ago, and they felt that
about 20% of kids were inadequately treated. And that's been the
standard number, about 20% even in sophisticated hospitals. And
as you could imagine, in low and middle resource countries, it's
80%, 90%, 100% of people don't have adequate pain management
especially around palliative care.
When you talk about palliative care, I'm sure some of the people
you'll interview will good at that, but that's completely
unbelievable in some of those countries where they don't even
have access to morphine. But in sophisticated hospitals it typically
runs, if you look at that literature, about 20% even now. You can't
really be perfect but then things are much better
For example, we did a study at Boston Children's extracting data
from the electronic medical record over two years and we had a
million pain ratings. Of those, we tried to look at those over 7 for
over a day or two, and that was less than a percent. And they fell in
very predictable patterns. Some were orthopedic kids, some of the
kids with what used to be called conversion or functional disorders
acute and chronic whatever you call it, and sickle cell kids. Those
were sort of the three arenas, and we developed sort of
interventions to address as best we can in all those arenas. But
anyway, so I think we're doing much better but there's still
probably still a ways to go and I would venture a guess. What
hospital are you in? Where are you now?
[00:54:44]
Bryan Sisk:
Neil Schechter:

[00:55:06]
Bryan Sisk:

Saint Louis Children's at WashU.
Yes, so I would venture a guess that even at your place, if we did
a blitz there would be people who were not satisfied with their
post-operative care. By the way, one of the leading guys on the
palliative care group that I remember was a guy named Sesh Coles
is he still there?
He's just retiring this year.
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So, he's a neonatologist and he represented that whole arena now
that I think about him. Anyway, so I would say that that was
changing, the recognition became increased gradually or pretty
dramatically the practice changed gradually.
Well take a step back thinking about palliative care and pain, they
were kind of developing with similar content area at about the
same time in pediatrics. What was the interaction when this
starting out in the late 80s early 90s? Was there a lot of cross talk
between the people that were pushing pediatric palliative care and
people that were developing pediatric pain as a specialty?
You're right on target. That's a great question. There was not.
There was hardly any cross talk which is sort of shocking, right,
depending on the institution. It was sort of shocking. Considering
in some institutions now they are in the same divisions, if you will.
But there wasn't a hell of a lot because a lot of the pediatric
palliative care work came out of oncology and so a lot of people
would come out of the oncology groups. What is that group now
called, COG? I don't know what that group is called now.
Yeah COG, the Children's Oncology Group.
Yeah so some of the work sort of came out from those kinds of big
people working in that. I know that a lot of the early people were
oncologists. I don't know if Joanne Wolfe started as an oncologist
but a lot of folks did and so it came out of that group. The pain
group came a little bit more of anesthesia at least in the beginning,
and even though it was sort of nursing, it tended to be less end-oflife care, although a ton of kids were dealing with
neurodegenerative diseases in the beginning or whatever. And
there were always these kids that would be screaming of unknown
origin of stuff that was attributed to pain but nobody could find it
and kids would develop mental problems.
But shockingly there was not a ton of crosstalk and there should
have been because the philosophies are so similar. So bio-psychosocial involved, being sure that the parents are brought in, the
language that's used. But so, for example one of the things that I
was really intriguing to me when we did this IOM report, what I
always took away from that—we interviewed a number of parents
who lost kids and when we asked them, "What would have made a
difference for you if anything. What would have made difference?"
And the parents who reported basically that they felt that they were
the general contractors and they had all these subcontractors, and
nobody was a general contractor.
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And that would have been the question who's that general
contractor? Is it the palliative care team? Is it the oncologist? Who
is it? We didn't have a similar coordination of care issues, if you
will, for most of our pain kids in the same sort of way. So it was a
little different in terms of marshalling of resources. It would be
mostly some drug choices, there would be some psych stuff, but it
wasn't bringing together the oncologists and interventional
radiologist and this that and the other and a GI [Gastroenterology]
doc—all those people that are necessary in coordinating the care of
some life threatening or life-limiting conditions. So it's a little bit
different, but shockingly there was little crosstalk and we could
have probably learned a lot from each other and still can, I think.
In our place now, there's only one of our pain doctors who's really
interested in oncology.
At this point the palliative care folks are pretty good at everything
except doing unusual catheter placements for kids with really
challenging kinds of problems that are really towards the end-oflife who they put in catheters hoping to make them comfortable or
do lysis block or another. But for the most part, most of the
medication management is done by palliative care, we don't see
many of those kids.
[01:00:01]
Bryan Sisk:

Neil Schechter:

So over time has this persisted as parallel tracks or diverging tracks
or has there ever been any additional cross talk between these
specialties?
Well, again I can only speak to my own experience, which is
limited, just in a few institutions. But for example, in our
institution there's comradery, but I would say not the sort of close
friendship that probably we would expect. That could be a function
of personalities; the person who runs the pain—it could be any
number of things in this particular setting. In the previous setting
where I was until 2010, there was a palliative care individual
oncologist who was working on really hospice related kinds of
stuff and we would do some of the pain management for her.
But I would say the symbiosis that should exist between the fields,
at least in the settings that I was in, is not as strong as it could be.
But I do, for example, I do lecture the palliative care folks. I have a
slot each year for the new fellows on pain management, but it's
really focused on chronic pain not so much on acute pain because
they have that down pretty well.
But that's a very interesting question and I've often thought about
like what you're doing, looking at the histories of both of these
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fields which were sort of came up in parallel. It was like
Neanderthals with Australopithecus, I’m sorry, I forgot what the
hell we are. And one them wasn't a dead end like Australopithecus
africanus, whatever the hell that was, was a dead end as we
evolved. So we evolved sort of together but never really
intermarried. But I know in certain places there are pain and
palliative like Yukon now there's a pain palliative doc and that's in
observational pain and palliative care and I bet that is so at other
sorts of places. Where I am, it's not.
[01:02:35]
Bryan Sisk:

Neil Schechter:

So from your perspective as you were forging a career in pediatric
pain before pediatric pain existed as a specialty, what were the
biggest challenges you faced?
Well, to be perfectly honest, I really didn't feel a lot of resistance.
I felt well accepted. I gave grand rounds all over the United States.
I felt relatively, with rare exceptions, relatively people heard what I
had to say and again in that era I was talking mostly about very
general kinds of things. The drugs themselves that people didn't
know much about. How to use morphine, how to assess
discomfort, that sort of stuff when I was talking about acute pain.
There was some really not a lot of resistance. I was able to frame
it. When you frame it from a patient experience point of view and
we're not accusatory, most people wanted to do the right thing.
And if you gave them that information, they were good with it and
that's why we developed all these consensus things and some were
put in place and some weren't put in place. But I wouldn't say,
obviously some of the surgeons had some resistance.
They were but almost immediately, for example, at Yukon very
quickly we were at the children's hospital. The pediatric surgeons
were really accepting of this and looking for help. I mean really
looking for help and in certain ways they felt closer to
pediatricians than they did to surgeons. Even the orthopedic
surgeons, they really were looking for help. And when we raised
that specter they said, "That is great." And so, I didn't really feel a
lot of—
It was an idea whose time had come and so I wouldn't say like
Joann Eland who encountered a lot of resistance, in part because
she was a nurse, she was a woman, she was telling docs what to
do. They didn't hear it and that person was very, very forceful. But
I felt done the right way, in an unaccusatory way providing
information, we could have significant impact. And that was with
rare exception, with rare exception.
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And so, having said all of that, there's still 20% of people are still
suffering needlessly and we haven't gotten very far with the needle
stuff yet. There's still been challenges to that with use of topical
anesthetic and stuff like that and who does the, who has to write
the order, this, that, the other thing. There are some of the obstacles
but for the most part, like in Boston Children's now we got 50 kids
a day on the acute pain service. The PCAs and some stuff like that
the surgeons are happy to do that. And we're doing regional stuff
that was another major advance.
So, I would say looking back at the length and breadth my career, I
mean, I was really felt accepted. We identified a gap in care.
People were looking for solutions. We could offer some solutions
and for the most part were accepting. Now again I worked in a
bubble and my chief of pediatrics was at Yukon. I mentioned the
other person Mark Richards previously, he was very accepting and
very supportive of my career. And then the chief of pediatrics at St.
Francis in Yukon was my best friend who was a fellow with me
and he was very supportive. So I never really felt a tremendous
amount of resistance to that.
Yeah funny when I think about it in that way. But I didn’t feel it.
And again publishing, it's an interesting thing maybe lesson for
your own career, when you identify an arena that's a bit under
researched, a thing if you will, this is what Mark would call it,
"You have to find a thing. " If you find a thing and publish a little
bit on that thing, suddenly before you know it, you're the person
who knows about that thing and especially if it's in an area that's
not—like what you're doing even now, I mean your history.
Suddenly you're known as the person who knows about that thing
and so you get invited to talk about it. And so we started with pain
awareness.
And then the other thing I didn't mention that was really very,
very, very helpful was in about 2001, 2002, it was JCAHO [Joint
Commission on Accreditation of Healthcare Organizations]. And
at that time, I forgot her name right now but she's another angel in
this field, a woman from the University of Wisconsin who's a
pharmacologist who was interested in pain. I forgot her name I'm
sorry. But anyway she nagged the hell out of JCAHO saying that
pain should be a marker, that pain should be included in how you
evaluate hospitals. Here is the data on patient experience.
Suddenly in 2001, 2002 people had to look at pain assessment,
looking
at
reassessment
as
well,
doing
AIR
[Assessment/Intervention/Reassessment]
cycles,
assessment,
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intervention, reassessment. And suddenly with all of that, pain
became a thing, and so we were kind of needed by the institutions.
They needed somebody to this, to develop protocols with them and
change practice. Because otherwise they wouldn’t to be approved
by JCAHO, and that was a big deal. That was a very big deal and
that was almost instant legitimacy.
Now, when you read the WHO publications from the people who
were into the opioid epidemic, discussing it that way, are claiming
that the pain is a fifth vital sign and all that stuff that people were
using, there was sort of ill intent. That definitely was not from my
perspective. Having said that, awakening everybody and asking
them about their pain after every four hours and having to respond
to it—typically, you're not going to respond with cognitive
behavior certainly. You're going to respond with an opioid and so
that might prime that pump a little bit. But anyway, I think JCAHO
is a critical aspect in the history of all this. The importance of a
governmental or quasi-governmental agency that holds a hospital's
livelihood in their hand and demanding that pain be attended to
was very helpful. On the other side of it there was all these reports
that hospital gets, you know they solicit these things. What are
they called? Some bunch of questionnaires that patients get when
they leave?
[01:10:20]
Bryan Sisk:

Neil Schechter:

[01:10:39]
Bryan Sisk:

Oh, the HCAHPS [Hospital Consumer Assessment of Healthcare
Providers and Systems].
Yeah, that sort of stuff, a number of those kinds of things. They're
asking about their experience and many people are reporting an
advocacy of pain management and that then empowers the
institution to sort of go ahead and do something and to ask for
something to be done about that. Some sort of intervention.
I got a couple of questions left and I'm going to frame the
questions related to kids that are suffering from serious illnesses.
If you feel like you can answer better for a different population,
take it whatever direction you want.

Neil Schechter:
[01:10:55]
Bryan Sisk:

Sure.

Neil Schechter:

Yeah, well again it isn't my area, but I will say the attention to
symptom control and to the psychological well-being of those kids

Over your career, what do you think has been the biggest changes
in the care provided for kids that suffering and even dying from
serious illnesses?
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has been dramatically, dramatically changed. Has dramatically
changed the kind of work you're doing, which is really God's work
really, has really had an impact. And when people can die, and
again staying with life-ending or life-limiting conditions, with
some sort of dignity at home, comfortable ,and again with
catheters, with adequate pain control, with adequate
psychological support, that has been a dramatic, dramatic impact.
I will say with other kinds of conditions so, for example, I work in
an abdominal pain clinic and we would see a lot of kids with IBD
who have pretty significant disease. Their disease is under control
but they continue to have persistent symptoms. Those kids I would
suggest, and I would suggest the same with JIA [Juvenile
idiopathic arthritis] and maybe the same with, post brain tumor
kids, post resections—those kids who no longer have either
increased inflammatory markers or active disease that we can
measure by present technology, they often have persistent
discomfort. I would say we don't do a great job with those kids.
We don't do a great job with those kids because we're still going
after what we perceive as the elephant in the room. Even though
the elephant has been addressed in a significant way and then you
tend to attribute it to psychological causes.
And it's easy to think that a kid with IBD who's going to run to the
bathroom every 20 minutes and doesn't want to go to school, and
now that's under control, but has gotten so far behind in school,
and the stress of catching up and explaining where they've been,
and this and the other thing, might be challenging so that they
would psychologically, even if they were better or not, not want to
go. Not infrequently but there's a hypersensitivity that has emerged
in their nerves as well and that piece needs to be addressed.
But I would say in terms of the kids you were talking about
primarily, the kids with life-limiting illness, that really from what I
saw in the past, horrible vomiting and mucositis that was untreated
or we did not know how to treat and other kinds of things. There's
been a much, much, much, much improved situation with that. So
we do get the rare kid who they’re really struggling with, but for
the most part either the palliative team or our team can do
something so that nobody really, so that most kids don't suffer
horribly and we can typically do something. Again, I'm not
speaking out of expertise so I'm not the right person to address, but
that's my sense and I have my eyes open a bit to that. But that's my
sense of in a place like ours, a place like Dana-Farber. I know
Joanne and those kinds of people could certainly talk to that more
in a more sophisticated way.
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And the last question, I would really love for you to dream aloud.
Thinking about children in pain in general, how you would want to
define it. If budget, politics, resource limitation, stereotypes, bias,
if all of these things weren't obstacles, what would you ideally
want care for children in pain to look like another ten years?
That's a great question. So I guess I'd see in a couple of different
arenas. So, in hospital and this happens for the most part now, but I
would say pretty much every procedure, there should't be any
procedure that kids are inadequately sedated for. And that includes
any sort of skin breaking procedure. So there definitely should be
adequate sedation, even for IV starts or even for blood draws or
anything like, that there should be topical anesthetic. So kids
shouldn't encounter discomfort. And I know it sort of as an
outpatient—you're a pediatrician. You're a pediatrician by training
so you've gone into the clinic right? And kids at the beginning of
your visit cowering, "Am I going to get shot? Am I going to get a
shot? Am I going to get a shot?" And that's all because of the sort
of preoccupation with needle with skin breaks. So I do think in
hospital for sure we can do a better job with—there should be no
procedures, zero procedures that cause much discomfort.
I think care needs to be decentralized around pain and that's sort of
a ChildKind thing that I'm talking about; that everyone is attentive
to when parents are asked, "What's the most important thing about
this hospitalization?" They will initially say, "Obviously curing my
child of whatever the disease is." But the second one would be,
"My child's comfort during the process." And when asked about
the level of satisfaction, the greatest disparity between their goal
and their satisfaction is in the area of comfort. So, it was 2008 or
'09 when that survey was done.
So, I do think decentralization of care where everybody is attentive
to it. People who bring the food trays, people who sweep the
floors, the nursing service, whatever. Everybody is aware of this
that there's accountability in a clear way for who's responsible for
keeping kids comfortable. Is it the attending at that level? Is it the
pain services or the nursing services? Where is the accountability
as somebody is struggling? I would certainly like to see that.
I think one of the problems that we're encountering now and that
you're going to encounter in a major way is this revolution with
opioids that are going on now, which is very, very, very
unfortunate and a gross over simplification of a complex problem.
Obviously Purdue was horrible at some of the things that they did,
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but this issue is not strictly that we have OxyContin. So it's a far
more complicated issue, yet opioids are being painted with a brush
and people with legitimate problems are afraid now of even the
short term use of opioids let alone people with life-ending illness
which is crazy. But we hear of that so I would like it to be a better
understanding of that. I would like most pain management to be
multidisciplinary. I did mention child life and stuff like that,
they're an absolutely critical piece of it. So that every hospital
would have adequate child life resources for them to be helping
them with anxiety around the hospitalizations itself and especially
around procedures.
So inpatient I would see a multidisciplinary approach and really
attention to post-operative management to lots more regional
anesthesia, which is a big deal and we're starting to use a
tremendous amount in our institution. The fact that most
procedures or every procedure is treated with something, either
it's nitrous or in some places local anesthetics where it's found to
be necessary or whatever. But that there's no build up like I
mentioned in my earlier study with bone marrows with anticipation
of the next procedure amplifying your discomfort.
As an outpatient, I do think again, skin breaking procedures is
another issue that as outpatient I feel is important. I think there are
other painful things that we routinely do as outpatients and some
attention to them might not be a bad idea. But I don't want to create
a bunch of kind of wimps—not to say that no one should ever feel
any discomfort that's ridiculous. And sometimes we can't alleviate
the pain in the hospital or whatever, there's still some. But
obviously we can typically do a better job.
There are all kinds of new research. My colleague is developing a
long-acting local anesthetic which will last for days, four days at a
time. So it can be used in the wound after surgery and you won't
really need other than non-steroidal downstream because it will
basically eliminate the discomfort in those nerves that have been
cut.
But anyway, there will be lots of other kinds of stuff I think
coming down the pike. I hope analgesics are not too stymied by the
concern of opioids. But I feel a trajectory of what we've done over
my lifetime has been dramatic. There was a paper I wrote. I quoted
a couple of papers. We were in the 80s, you looked at the number
of articles that were published on pediatric pain, it was like five or
ten or something, and half of them were mine or somebody.
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Very, very few in the pediatric literature per se. And now when
you look, a lot was in the nursing literature or whatever, but now
when you look there's thousands, on pediatric pain thousands. And
the scope has been quite dramatic. When we started, somebody
named Rana wrote another letter to the editor 5 maybe to
Pediatrics, or something like that. And this person looked at the
top ten pediatric textbooks. This was in the late-80s I think, early90s, and found in all of the top pediatric textbooks, there was like
ten different textbooks, a total of a page and a half that was
devoted to pain and a chunk on that was on sickle cell. So there
was nothing in that.
There was no advice of what about what to do. Whatever there was
nothing there. And now there are multiple textbooks on pain every
chapter. There are pediatric texts lots of people have written them.
The major pediatric textbooks have chapters on pain, and you’ll
see some chapters on development and stuff like that. So, the
uptake has been very, very dramatic. I anticipate the continued
growth.
One of the issues we are facing, and again this is more inside
baseball, but it in the world of pediatric pain you can't be board
certified unless you've done an anesthesia fellowship a neurology
fellowship or PMR [Physical Medicine and Rehabilitation]
fellowship. So a pediatrician couldn't be board certified in pain
because it comes out of anesthesia. We're trying to change that, a
group of us, so that pediatricians could take a pain fellowship and
be boarded in pain subsequently, but that might have a real
negative impact. It's having a negative impact and it's hard for us to
find pediatricians per se with an interest in this arena. So, we're
trying to grow some to replace ourselves
But in particular that's sort of an issue. So, manpower is going to
be an issue. Another thing I'm writing there's a Lancet commission
on pediatric pain that we're just getting started with it writing a
section on it on organization of care. And certainly there will be
more and more things on telehealth, and internet based care,
internet based CBT [Cognitive behavioral therapy] in the future to
address chronic and persistent pain problems. I think those are
inevitable. I think as I mentioned there will be new medications
and again the importance of a multidisciplinary approach—this
can't be understated.
[01:24:25]
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I got one other question that came to mind that I would love to ask
you.
Sure.
Thinking again about five years or ten years from now, what do
you think would be the ideal interaction and relationship between
pediatric pain medicine and pediatric palliative care?
Well, I would see—I mean they're so similar in so many ways that
I would see if it at all possible, I don't want to diminish one or the
other, but one being under joint leadership if at all possible and
something independent. Whatever we wanted to call that division,
symptom control or whatever. But they would share ground
rounds. We don't do that where we are right now which is crazy.
They'd share journal clubs, they'd share the rotation for our pain
program—and there is for our pain fellows, they have to spend
some time in palliative care. Yes, they do, but it would be a much
more important part of the rotation.
I don't think the palliative care folks spend any time with us to be
perfectly honest. It's not bidirectional at this juncture but I would
say spending time during the fellowships with each of us, because
there's a lot to learn from each other. We have, for example, once a
month I would say, we have joint surgery and anesthesia ground
rounds. Why we have not joint pain and palliative care ground
rounds, every twice a year or something? It doesn't make any
sense. Or more frequently than that. So I would say we have a lot
to learn from each.
I don't know about the defensiveness, "You're doing my stuff, I'm
doing your stuff," how we tamp that down where it exists. I don't
know where totally it exists but I'm guessing. The fact that we
don't see a lot of kids with cancer suggests for the most part their
pain management is being handled in palliative care, so I don't
know. But I would say certainly a closer relationship makes sense.
And as pain medicine is becoming much more anesthesia focused
unfortunately. That's our big problem now but it is—a lot of the
training is in anesthesia. They can bring something that the
palliative care folks don't have but they don't have a lot of else, so
they really would benefit from our anesthesia colleagues but from
some traditional training through palliative care.
But anyway that's where I worry the fields might be moving a part
in terms of the personnel because anesthesia, they don't like to live
in ambiguity. They like to tuck things in at the end of the day. A
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clear beginning and an end. They like to help and know that they're
helping. And with pain and with palliative care, that isn't usually
so, especially chronic pain and palliative care in general, these
problems are ambiguous at times, they're draining, they're
emotionally draining. Sometimes the families have a hard time
being grateful or appreciative. They're sometimes angry given the
lot that they felt they'd been dealt, the cards they've been dealt. So I
do think the temperament of personality of people going into pain
is quite different than the people going to palliative care. So, I'm
not sure what that's going to do to the relationship honestly.
And I don't know what funds are going to drive them either at the
other kind of thing where depending on coding and an additional
support. I don't know what that’s going to make things more or less
procedure driven or more or less viable. It's interesting times.
[01:28:48]
Bryan Sisk:

Neil Schechter:

Absolutely, this has been phenomenal. Those are all my questions
but is there anything else about this history that you think that I'm
really missing or any gaps I haven't been aware of?
No, I think I've covered most of them. I may not have remembered
certain things, but I certainly have gone on about myself. I'm
interested though in how you came to this because that's a
remarkably, to my way of thinking, quite a sophisticated—a, your
questions are very sophisticated, your understanding is
sophisticated, but how you came as an oncology fellow to looking
at the history of these kinds of things is intriguing to me.
[End of Audio]

